Rankings
▼
Calendar
BMRN Q3 2020 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena
BMRN
BioMarin Pharmaceutical Inc.
$12B
Q3 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$477M
+3.4% YoY
Gross Profit
$288M
60.4% margin
Operating Income
-$56M
-11.7% margin
Net Income
$785M
164.6% margin
EPS (Diluted)
$4.01
QoQ Revenue Growth
+11.0%
Cash Flow
Operating Cash Flow
$86M
Free Cash Flow
$70M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$6.2B
Total Liabilities
$2.1B
Stockholders' Equity
$4.1B
Cash & Equivalents
$1.0B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$477M
$461M
+3.4%
Gross Profit
$288M
$364M
-20.9%
Operating Income
-$56M
$4M
-1495.0%
Net Income
$785M
$55M
+1326.0%
Revenue Segments
Royalty And Other
$16M
100%
Geographic Segments
UNITED STATES
$253M
53%
Europe
$121M
25%
Rest Of World
$59M
12%
Latin America
$44M
9%
← FY 2020
All Quarters
Q4 2020 →